Drug Profile
Research programme: anticancer therapeutics - Tigris
Alternative Names: GFB-204Latest Information Update: 16 Jul 2016
Price :
$50
*
At a glance
- Originator H. Lee Moffitt Cancer Center and Research Institute; University of South Florida; Yale University
- Developer Kirax Corporation
- Class Macrocyclic compounds
- Mechanism of Action Angiogenesis inhibitors; Platelet-derived growth factor inhibitors; Vascular endothelial growth factor A inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Solid tumours
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for preclinical development in Solid-tumours in USA (PO)
- 11 May 2007 Data presented at the 98th Annual Meeting of the American Association for Cancer Research (AACR 2007) added to the Cancer pharmacodynamics section
- 12 Jul 2006 Preclinical trials in Solid tumours in USA (PO)